Analysts Have Conflicting Sentiments on These Healthcare Companies: Nektar Therapeutics (NASDAQ: NKTR), Embecta Corporation (NASDAQ: EMBC) and Replimune Group (NASDAQ: REPL)We also discussed recent trends in the insulin administration market both in the U.S. and outside of the U.S. as well as the company's capital allocation priorities. We believe EMBC has successfully executed against its near-term objectives and look forward to more updates on longer-term initiatives that may support EMBC's next phase of growth. We continue to think EMBC is undervalued, underscoring the company's dividend yield, its strong free cash flow generation, focused debt paydown efforts, and mid-to-long term pipeline opportunities. Reiterate Buy.